Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

Also called NCT01704079

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 216 participants (enrolled count) (from the registry)
Sponsor
OPKO IP Holdings II, Inc. (from the registry)
Registry
  • NCT NCT01704079
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01704079. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2016-08-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
Condition
Hyperparathyroidism, Secondary
Condition
Vitamin D Deficiency
Intervention (Drug)
CTAP101 30 μg capsules
Intervention (Other)
Sugar pill to CTAP101 30 μg capsules
Lead sponsor
OPKO IP Holdings II, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01704079
Content hash
d2dc54234c535d31b8098cf7c60aa47ccca9d0c00be21191367d43c899b0b2b1